CCDM Regulatory Requirements 2 — Questions and Answers
Question 1: Under 21 CFR Part 11, which technical control is specifically required for electronic signatures used in clinical data systems?
- A unique identifier combined with a password or biometric (Correct answer)
- A handwritten signature scanned and stored digitally
- A PIN code sent via SMS to the user's mobile device
- An IP address log tied to the user's login session
Correct answer: A unique identifier combined with a password or biometric
21 CFR Part 11 requires electronic signatures to consist of at least two distinct identification components, such as a unique identifier combined with a password or biometric.
Question 2: Which ICH guideline specifically addresses the statistical principles for clinical trials, relevant to data management planning?
- ICH E9 (Correct answer)
- ICH E6
- ICH E3
- ICH E8
Correct answer: ICH E9
ICH E9 covers statistical principles for clinical trials, guiding how clinical data should be collected, handled, and analyzed.
Question 3: When a sponsor makes a change to an already-approved protocol, what regulatory document must be submitted to the IRB before implementing the change?
- A protocol amendment (Correct answer)
- A deviation report
- A safety update report
- A CIOMS form
Correct answer: A protocol amendment
Protocol amendments must be submitted to and approved by the IRB before any changes are implemented, unless they are necessary to eliminate immediate hazards.
Question 4: According to FDA regulations, how long must a sponsor retain essential clinical trial records after the marketing application is approved or discontinued?
- 2 years (Correct answer)
- 5 years
- 7 years
- 10 years
Correct answer: 2 years
FDA 21 CFR 312.62 requires sponsors to retain records for at least 2 years after a marketing application is approved, or 2 years after the IND is withdrawn if no application is filed.
Question 5: Which regulation governs the protection of individually identifiable health information in the context of clinical research in the US?
- HIPAA Privacy Rule (Correct answer)
- 21 CFR Part 50
- ICH E6 R2
- The Belmont Report
Correct answer: HIPAA Privacy Rule
The HIPAA Privacy Rule establishes standards for the protection of individually identifiable health information, including in clinical research settings.
Question 6: In the context of GCP, who is ultimately responsible for the conduct of a clinical trial at a study site?
- The principal investigator (Correct answer)
- The sponsor's monitor
- The IRB/IEC
- The clinical data manager
Correct answer: The principal investigator
Under GCP, the principal investigator is ultimately responsible for the conduct of the clinical trial at their site.
Question 7: What is the primary purpose of a Data Safety Monitoring Board (DSMB) in clinical trials?
- To monitor accumulating data for participant safety and trial integrity (Correct answer)
- To review and approve all data entry into the EDC system
- To audit the sponsor's data management procedures
- To ensure HIPAA compliance for trial participants
Correct answer: To monitor accumulating data for participant safety and trial integrity
A DSMB independently monitors accumulating safety and efficacy data to recommend continuation, modification, or termination of a trial to protect participants.
CCDM Regulatory Requirements 2
Under 21 CFR Part 11, which technical control is specifically required for electronic signatures used in clinical data systems?